Literature DB >> 16960324

The coverage priorities of disabled adult Medi-Cal beneficiaries.

Marion Danis1, Marjorie Ginsburg, Susan Dorr Goold.   

Abstract

Medi-Cal, like other Medicaid programs around the U.S., has been pressed to cut its budget. We report the results of a project using the CHAT (Choosing Healthplans All Together) exercise, designed to ascertain the priorities of disabled adult Medi-Cal beneficiaries to inform any decisions regarding Medi-Cal benefits. Participants voiced greatest interest in maintaining a wide spectrum of benefits and access to a large pool of providers and were most willing to restrict pharmacy benefits. The resulting findings may be of value to legislators drafting Medicaid proposals that revise benefits for this vulnerable population.

Entities:  

Mesh:

Year:  2006        PMID: 16960324     DOI: 10.1353/hpu.2006.0103

Source DB:  PubMed          Journal:  J Health Care Poor Underserved        ISSN: 1049-2089


  4 in total

1.  Experience in the United States with public deliberation about health insurance benefits using the small group decision exercise, CHAT.

Authors:  Marion Danis; Marjorie Ginsburg; Susan Goold
Journal:  J Ambul Care Manage       Date:  2010 Jul-Sep

2.  Financial Protection in Health Insurance Schemes: A Comparative Analysis of Mediclaim Policy and CHAT Scheme in India.

Authors:  Sukumar Vellakkal
Journal:  J Health Manag       Date:  2012-03-01

3.  Evaluating community deliberations about health research priorities.

Authors:  Susan Dorr Goold; Marion Danis; Julia Abelson; Michelle Gornick; Lisa Szymecko; C Daniel Myers; Zachary Rowe; Hyungjin Myra Kim; Cengiz Salman
Journal:  Health Expect       Date:  2019-06-28       Impact factor: 3.377

4.  How Would Low-Income Communities Prioritize Medicaid Spending?

Authors:  C Daniel Myers; Edith C Kieffer; A Mark Fendrick; Hyungjin Myra Kim; Karen Calhoun; Lisa Szymecko; Lynnette LaHahnn; Charo Ledón; Marion Danis; Zachary Rowe; Susan Dorr Goold
Journal:  J Health Polit Policy Law       Date:  2020-06-01       Impact factor: 2.977

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.